← Back to Search

Strategies for PrEP Uptake in Emergency Departments for HIV Prevention (ED2PrEP Trial)

N/A
Recruiting
Led By Viraj V Patel, MD, MPH
Research Sponsored by Albert Einstein College of Medicine
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 18 months
Awards & highlights

ED2PrEP Trial Summary

This trial seeks to improve HIV prevention in at-risk communities by increasing access to PrEP in Emergency Departments.

Who is the study for?
This trial is for adults over 18 who visit the Emergency Department with concerns related to sexual health. It aims to help communities heavily affected by HIV, especially where there's a gap in access to prevention methods. People unable to give informed consent cannot participate.Check my eligibility
What is being tested?
ED2PrEP tests two new strategies (PVO and TS) for increasing uptake of PrEP, a medication that prevents HIV, among patients seeking care for sexually transmitted infections in emergency departments located in areas with high rates of HIV.See study design
What are the potential side effects?
The summary does not specify side effects; however, common side effects of PrEP can include nausea, headache, stomach pain, and weight loss. Most are mild and tend to resolve over time.

ED2PrEP Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~18 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 18 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
PrEP Uptake
Secondary outcome measures
HIV Vaccine
HIV and STI testing
HIV
+4 more

ED2PrEP Trial Design

2Treatment groups
Experimental Treatment
Group I: Tele-Sexual Healthcare (TSH) visit during the ED visitExperimental Treatment1 Intervention
Tele-sexual health visit with a specialist offered during the ED visit to patients.
Group II: Post Visit Outreach (PVO)Experimental Treatment1 Intervention
Outreach by trained patient navigators/educators after patients' ED visit for education, counseling, linkage to preventive/sexual health care.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
TSH
2014
N/A
~1530

Find a Location

Who is running the clinical trial?

National Institute of Allergy and Infectious Diseases (NIAID)NIH
3,272 Previous Clinical Trials
5,484,180 Total Patients Enrolled
Albert Einstein College of MedicineLead Sponsor
287 Previous Clinical Trials
11,855,692 Total Patients Enrolled
Viraj V. PatelLead Sponsor

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are individuals still able to sign up for this investigation?

"According to the information available on clinicaltrials.gov, this investigation is not taking part in recruitment currently. It was initially posted on November 1st 2023 and last updated October 26th of that same year. Although no enrollment opportunities are present right now, there are 436 other trials actively looking for participants."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
ED2PrEP - Patient Focused, Low-burden Strategies for PrEP Uptake Among Emergency Departments
Viraj V. Patel 2024. "ED2PrEP - Patient Focused, Low-burden Strategies for PrEP Uptake Among Emergency Departments". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05588193.
~944 spots leftby Jan 2026
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top